HLB Life Science Co., Ltd. (KOSDAQ:067630)
South Korea · Delayed Price · Currency is KRW 3,105.00
+130.00 (4.37%)
Jun 9, 2026, 3:30 PM KST
HLB Life Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 51,512 | 45,752 | 32,771 | 97,990 | 99,591 | 53,494 |
Other Revenue | - | - | - | - | 0 | 0 |
| 51,512 | 45,752 | 32,771 | 97,990 | 99,591 | 53,494 | |
Revenue Growth (YoY) | 46.49% | 39.61% | -66.56% | -1.61% | 86.17% | -41.73% |
Cost of Revenue | 53,169 | 46,474 | 36,405 | 98,915 | 102,813 | 59,155 |
Gross Profit | -1,657 | -721.6 | -3,634 | -925.04 | -3,222 | -5,661 |
Selling, General & Admin | 13,782 | 13,855 | 12,458 | 15,226 | 10,839 | 8,247 |
Research & Development | 4,593 | 4,697 | 5,177 | 5,454 | 4,349 | 3,846 |
Amortization of Goodwill & Intangibles | 563.16 | 454.32 | 182.4 | 990.25 | 591.41 | 8.01 |
Other Operating Expenses | 405.84 | 382.1 | 351.11 | 279 | 192.67 | 113.46 |
Operating Expenses | 20,160 | 20,314 | 16,350 | 24,568 | 16,728 | 12,668 |
Operating Income | -21,816 | -21,035 | -19,984 | -25,493 | -19,950 | -18,329 |
Interest Expense | -12,264 | -11,744 | -16,798 | -21,650 | -9,870 | -1,256 |
Interest & Investment Income | 1,965 | 2,241 | 1,356 | 1,288 | 1,203 | 512.76 |
Earnings From Equity Investments | 2,501 | 2,406 | 1,354 | -2,537 | 2,602 | - |
Currency Exchange Gain (Loss) | -29.72 | -169.5 | 121.23 | -93.22 | 33.77 | -4.05 |
Other Non Operating Income (Expenses) | 374.28 | 372.86 | 101.69 | 469.76 | -2,664 | -60.63 |
EBT Excluding Unusual Items | -29,270 | -27,928 | -33,848 | -48,015 | -28,646 | -19,137 |
Gain (Loss) on Sale of Investments | -11,660 | -63,329 | 61,652 | 81,336 | -20,548 | -21,296 |
Gain (Loss) on Sale of Assets | -3,295 | -3,236 | 10.31 | -304.96 | 3,157 | 594.55 |
Asset Writedown | -6,073 | -6,073 | -24,162 | -37,553 | -14,802 | -13,786 |
Other Unusual Items | 44.76 | - | - | -1,966 | - | - |
Pretax Income | -50,254 | -100,566 | 3,652 | -6,503 | -60,839 | -53,624 |
Income Tax Expense | 356.7 | -666.74 | -3,058 | -590.06 | -6,479 | -4,333 |
Earnings From Continuing Operations | -50,611 | -99,899 | 6,710 | -5,913 | -54,360 | -49,292 |
Earnings From Discontinued Operations | 85.3 | -44.95 | -503.11 | - | - | - |
Net Income to Company | -50,526 | -99,944 | 6,207 | -5,913 | -54,360 | -49,292 |
Minority Interest in Earnings | 73.89 | 149.97 | -68.89 | -70.35 | 82.24 | 139.89 |
Net Income | -50,452 | -99,794 | 6,138 | -5,983 | -54,277 | -49,152 |
Net Income to Common | -50,452 | -99,794 | 6,138 | -5,983 | -54,277 | -49,152 |
Shares Outstanding (Basic) | 122 | 122 | 112 | 102 | 101 | 99 |
Shares Outstanding (Diluted) | 122 | 122 | 112 | 102 | 101 | 99 |
Shares Change (YoY) | 6.75% | 9.22% | 9.65% | 0.80% | 1.64% | 0.34% |
EPS (Basic) | -413.72 | -818.74 | 55.00 | -58.79 | -537.56 | -494.76 |
EPS (Diluted) | -413.72 | -818.74 | 55.00 | -59.00 | -537.56 | -494.76 |
Free Cash Flow | -43,030 | -48,515 | -59,301 | -30,634 | -40,420 | -16,505 |
Free Cash Flow Per Share | -352.86 | -398.03 | -531.38 | -300.99 | -400.32 | -166.14 |
Gross Margin | -3.22% | -1.58% | -11.09% | -0.94% | -3.23% | -10.58% |
Operating Margin | -42.35% | -45.98% | -60.98% | -26.02% | -20.03% | -34.26% |
Profit Margin | -97.94% | -218.12% | 18.73% | -6.11% | -54.50% | -91.88% |
Free Cash Flow Margin | -83.53% | -106.04% | -180.96% | -31.26% | -40.59% | -30.85% |
EBITDA | -15,298 | -15,788 | -14,083 | -17,797 | -14,727 | -15,845 |
EBITDA Margin | -29.70% | -34.51% | -42.97% | -18.16% | -14.79% | -29.62% |
D&A For EBITDA | 6,518 | 5,247 | 5,901 | 7,696 | 5,223 | 2,484 |
EBIT | -21,816 | -21,035 | -19,984 | -25,493 | -19,950 | -18,329 |
EBIT Margin | -42.35% | -45.98% | -60.98% | -26.02% | -20.03% | -34.26% |
Advertising Expenses | - | 70.49 | 96.93 | 157.86 | 69.13 | 34.92 |